Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Arcellx

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death

The FDA placed a study of Arcellx's multiple myeloma drug on hold after a patient died, leading ACLX stock to crumble Tuesday.

Investors Business Daily

Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences

Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences

Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

More Than $6 Million Bet On JELD-WEN Holding? 3 Stocks Insiders are Buying

Although the US stocks closed higher on Thursday, there were a few notable insider trades.

How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer

Newcomer Arcellx could rival Johnson & Johnson in multiple myeloma, an analyst said as the biotech popped to a two-month high.

Investors Business Daily

Expert Ratings for Arcellx

Analysts have provided the following ratings for Arcellx (NASDAQ:ACLX) within the last quarter:

Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma

Arcellx, Inc. (NASDAQ: ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma (r/r MM).

inkl

Read news from The Economist, FT, and more,
with one subscription

BofA Initiates Arcellx With Buy On Its Novel Therapy Approach

BofA Initiates Arcellx With Buy On Its Novel Therapy Approach

Arcellx (NASDAQ: ACLX) is advancing into pivotal testing (by year-end 2022) of its B-cell maturation antigen (BCMA) directed combination antiretroviral therapy (CART), known as ddBCMA, for relapsed refractory multiple myeloma, according to BofA Securities.

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022

CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19

CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19

CAR-T company Arcellx Inc (NASDAQ: ACLX) priced its IPO at

1

Organisations

Johnson & Johnson (

Advanced Micro Devices

Paramount Global

BofA Securities

Gilead Sciences

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

162,003 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play